Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study

Sissel J. Godtfredsen*, Harman Yonis, Joachim Baech, Nour R. Al-Hussainy, Signe Riddersholm, Lars Kober, Morten Schou, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, Peter Kamper, Caroline E. Dietrich, Mikkel Porsborg Andersen, Christian Torp-Pedersen, Peter Sogaard, Tarec Christoffer El-Galaly, Kristian H. Kragholm

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment is unclear. cHL patients ≥ 18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000 and 2022 were matched 1:5 with comparators on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥ 1). Cause-specific cumulative incidence of a composite of CVDs with corresponding 95% confidence intervals (CIs) were computed with death and lymphoma relapse as competing events (i.e., by censoring individuals at such occurrences) using the Aalen-Johansen estimator. A total of 1905 patients and 9525 comparators with a median follow-up of 10 years (interquartile range, [IQR]: 5.9-17.4). Median age was 39 years (IQR: 27-56), median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200-300). The CVD cumulative incidences were 4.7% (95% CI: 3.6-5.7) for patients versus 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) versus 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) versus 8.2% (95% CI: 7.4-9.0) at 15 years. CVD remains a substantial effect after contemporary treatment for cHL, suggesting that awareness of symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.

Original languageEnglish
JournalEuropean Journal of Haematology
Volume114
Issue number2
Pages (from-to)343-352
Number of pages10
ISSN0902-4441
DOIs
Publication statusPublished - Feb 2025

Bibliographical note

© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.

Keywords

  • Hodgkin lymphoma
  • cardiotoxicity
  • late effects of treatment

Fingerprint

Dive into the research topics of 'Risk of Cardiovascular Disease in Patients With Classical Hodgkin Lymphoma: A Danish Nationwide Register-Based Cohort Study'. Together they form a unique fingerprint.

Cite this